Drugs / FT825
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06241456 | Jan 2024 → May 2029 expected | neoplasm | Fate Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT825 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06241456 ↗ |
| Known as | ONO-8250 | “ONO-8250” NCT06241456 ↗ |
| Modality | Cell therapy | “FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors” NCT06241456 ↗ |
| Route | Intravenous | “FT825 will be administered as an intravenous (IV) infusion” NCT06241456 ↗ |